|
Market Closed -
NYSE
21:03:31 26/08/2026 BST
|
Pre-market 14:14:00 | |||
| 114.10 USD | -1.75% |
|
113.09 | -0.89% |
| 08-26 | Analyst recommendations: Nvidia, Intuit, BofA, Abbott Laboratories, Google… |  |
| 08-26 | Boston Scientific hit by cyberattack, global operations affected | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 197,437 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -9.37% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 221,376 | 218,394 | 214,704 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -0.4% | -1.35% | -1.69% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 32.7x | 25.2x | 22.5x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 4.12x | 3.95x | 3.75x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.2x | 0.8x | 1.9x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.93x | 3.61x | 3.38x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.4x | 4x | 3.68x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 16.9x | 15x | 13.4x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 18.9x | 16.8x | 15x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 27.9x | 23.3x | 21x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.58% | 4.28% | 4.76% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.25% | 2.4% | 2.54% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.486 | 4.524 | 5.074 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.7% | 60.6% | 57.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,302 | 54,646 | 58,409 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,090 | 14,598 | 16,020 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,719 | 13,021 | 14,313 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,232 | 7,924 | 8,850 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 114.10 | 114.10 | 114.10 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.73x | 4.4x | 16.91x | 2.25% | 197B | |
| 20.72x | 3.58x | 12.64x | 3.23% | 118B | |
| 17.95x | 0.21x | 13.08x | 0.73% | 62.55B | |
| 30.43x | 7.56x | 19.31x | 1.31% | 52.4B | |
| 36.65x | 3.51x | 12.03x | 2.06% | 51.81B | |
| 35.66x | 6.27x | 19.69x | -.--% | 33.57B | |
| 45.39x | 1.29x | 11.79x | 0.17% | 30.34B | |
| 40.81x | 7.15x | 25.65x | 0.26% | 24.63B | |
| 19.87x | 3.06x | 11.18x | 1.44% | 23.81B | |
| 25.5x | 3.84x | 13.48x | 1.12% | 23.09B | |
| Average | 30.57x | 4.09x | 15.58x | 1.26% | 61.74B | |
| Weighted average by Cap. | 29.41x | 4.00x | 15.40x | 1.81% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
